EUVIMEDEUVIMED entdecken
Crossref

In vitro hemolytic performance of the Realheart® V11C TAH prototype with porcine blood

Ina Laura Perkins iD, Eva Maria Mansisidor iD, Shaikh Faisal Zaman iD, Kyle Mudge iD, Owen Bodger iD, Azad Najar iD

Artificial Organs · 2023

DOI: 10.1111/aor.14533 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Artificial Organs, 2023. Verfasst von Ina Laura Perkins und 5 weiteren Autor:innen. Beteiligte Einrichtung: R&D, Scandinavian Real Heart AB, Västerås, Sweden. Hauptthemen laut MEDLINE: Heart, Artificial, Heart Failure, Heart-Assist Devices. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 29 Literaturangaben. Gefördert von: Scandinavian Real Heart.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Hemolysis testing of new devices to treat heart failure is a regulatory requirement. The ASTM F1841–97 standard for hemolysis testing was developed for continuous flow pumps and does not specify test rig design. When research groups use different methodologies, results are difficult to compare. Pulsatile flow pump rigs require compliance chambers, and thus, the Aachen rig (Gräf et al) was developed for the pulsatile Reinheart TAH. The study objective was to use this rig to test the early Realheart TAH prototype V11C hemolysis performance compared to literature.

Methods

The experimental control was the continuous flow pump BPX‐80 (Medtronic) and pooled heparinized porcine blood was used.

Results

The mgNIH of BPX‐80 and V11C was 5.42 ± 1.47 and 25.20 ± 5.46 mg/100 L, respectively. The NIH ratio of V11C over BPX‐80 was 5.5.

Conclusion

The absolute and the relative hemolysis of the V11C are lower compared to both the large and small Reinheart TAH devices published values. Pulsatile pumps create more hemolysis in the Aachen rig, and it is not known if this is because how the rig handles pulsatile flow or due to the devices. Future studies will, therefore, use a pulsatile pump such as the SynCardia as clinical comparator and human blood to test the performance of future Realheart TAH prototypes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Heart, ArtificialHeart FailureHeart-Assist DevicesAnimalsSwineHumansHemolysisPulsatile Flow

Stichwörter der Autor:innen

BPX-80Realhearthemolysisporcinetotal artificial heart

Autor:innen und Institutionen

  • R&D, Scandinavian Real Heart AB, Västerås, Sweden.
  • Institute of Life Science, Swansea University Medical School, Swansea, UK.

ORCID-Profile: Ina Laura Perkins, Eva Maria Mansisidor, Shaikh Faisal Zaman, Kyle Mudge, Owen Bodger, Azad Najar

Förderung

  • Scandinavian Real Heart

Zitieren

APA

Perkins, I. L., Mansisidor, E. M., Zaman, S. F., Mudge, K., Bodger, O., & Najar, A. (2023). In vitro hemolytic performance of the Realheart® V11C TAH prototype with porcine blood. Artificial Organs. https://doi.org/10.1111/aor.14533

Vancouver

Perkins IL, Mansisidor EM, Zaman SF, Mudge K, Bodger O, Najar A. In vitro hemolytic performance of the Realheart® V11C TAH prototype with porcine blood. Artificial Organs. 2023. doi:10.1111/aor.14533

BibTeX
@article{Perkins2023,
  author = {Perkins, Ina Laura and Mansisidor, Eva Maria and Zaman, Shaikh Faisal and Mudge, Kyle and Bodger, Owen and Najar, Azad},
  title = {In vitro hemolytic performance of the Realheart® V11C TAH prototype with porcine blood},
  journal = {Artificial Organs},
  year = {2023},
  doi = {10.1111/aor.14533}
}
Kostenlos starten →